1. Home
  2. FRAF vs HELP Comparison

FRAF vs HELP Comparison

Compare FRAF & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Financial Services Corporation

FRAF

Franklin Financial Services Corporation

HOLD

Current Price

$58.75

Market Cap

255.8M

Sector

Finance

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$5.65

Market Cap

249.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRAF
HELP
Founded
1906
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.8M
249.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FRAF
HELP
Price
$58.75
$5.65
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$51.50
AVG Volume (30 Days)
31.3K
688.4K
Earning Date
04-23-2026
07-01-2026
Dividend Yield
2.26%
N/A
EPS Growth
88.84
N/A
EPS
4.74
N/A
Revenue
N/A
N/A
Revenue This Year
$14.44
N/A
Revenue Next Year
$6.95
N/A
P/E Ratio
$12.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.44
$4.29
52 Week High
$58.64
$8.55

Technical Indicators

Market Signals
Indicator
FRAF
HELP
Relative Strength Index (RSI) 69.27 57.24
Support Level $47.15 $4.40
Resistance Level N/A $8.55
Average True Range (ATR) 1.78 0.30
MACD 0.45 0.13
Stochastic Oscillator 90.09 79.09

Price Performance

Historical Comparison
FRAF
HELP

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: